---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-121497"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:14:14.730706+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# New US law to materially hurt InMed's BayMedica cannabinoid business; core pharma programs unaffected

## Summary
- H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.
- BayMedica is evaluating alternative supply chain options to maintain regulatory compliance.
- InMed's pharmaceutical programs (INM-901 for Alzheimer's, INM-089 for AMD) are not affected by the legislation.
- Company warns of material negative impact on BayMedica's contribution to consolidated financial results.
- Act may be amended before Nov 12, 2026, but current form already enacted.

## SEC filing metadata
- accession: 0001213900-25-121497
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025121497/0001213900-25-121497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025121497/ea0269687-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-121497
- JSON: https://secwatch.observer/filing/0001213900-25-121497.json
- Plain text: https://secwatch.observer/filing/0001213900-25-121497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.